Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06149169

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed and Refractory (R/R) LBCL

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.

Conditions Diffuse Large B Cell Lymphoma Lymphoma, Non-Hodgkin

Interventions CD19-targeted Chimeric Antigen Receptor(CAR) T Cells

Updated 4 times since 2023 Last updated: Aug 19, 2024 Started: Aug 17, 2023 Primary completion: Oct 30, 2024 Completion: Mar 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diffuse Large B Cell Lymphoma and Lymphoma, Non-Hodgkin and is currently ongoing. Shanghai Ming Ju Biotechnology Co., Ltd. leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Apr 2024 [monthly]

Recruiting PHASE2

First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Ming Ju Biotechnology Co., Ltd.

Data source: Shanghai Ming Ju Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China